We believe that GLP-1 drugs are one of the most important technologies of the next five years
In a 12-week study, participants receiving 1 mg daily lost an average of 2.6 kg (approximately 5.7 pounds) compared to 0.8 kg in the placebo group
The right option depends on the patients health history, BMI, metabolic markers, current medication, and treatment goals
Longer term For longer protocols, review trends every 3-6 months with a clinician
Alterations of the predominant fecal microbiota and disruption of the gut mucosal barrier in patients with early-stage colorectal cancer
Its GABAergic mechanism, anxiolytic research documentation, and official Russian approval as an anxiolytic drug make it the clear choice for research exploring anxiety, stress, and related neurochemical pathways